Merck-and-Company is a drug manufacturers - general business based in the US. Merck-and-Company shares (MRK) are listed on the NYSE and all prices are listed in US Dollars. Merck-and-Company employs 70,000 staff and has a trailing 12-month revenue of around $61.4 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $125.85 |
|---|---|
| 52-week range | $97.23 - $134.63 |
| 50-day moving average | $129.23 |
| 200-day moving average | $117.70 |
| Wall St. target price | $142.98 |
| PE ratio | 144.2445 |
| Dividend yield | $2.96 (2.37%) |
| Earnings per share (TTM) | $0.90 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $125.85 from 2024-07-03
| 1 week (2024-06-28) | 1.66% |
|---|---|
| 1 month (2024-06-05) | -2.78% |
| 3 months (2024-04-05) | -1.67% |
| 6 months (2024-01-05) | 7.36% |
| 1 year (2023-07-05) | 10.69% |
|---|---|
| 2 years (2022-07-05) | 35.85% |
| 3 years (2021-07-02) | 60.11% |
| 5 years (2019-07-05) | 63.93% |
Valuing Merck-and-Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merck-and-Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Merck-and-Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 144x. In other words, Merck-and-Company shares trade at around 144x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Merck-and-Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.1008. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merck-and-Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Merck-and-Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $21.2 billion.
The EBITDA is a measure of a Merck-and-Company's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $61.4 billion |
|---|---|
| Operating margin TTM | 42.47% |
| Gross profit TTM | $42.1 billion |
| Return on assets TTM | 10.26% |
| Return on equity TTM | 5.31% |
| Profit margin | 3.76% |
| Book value | $15.94 |
| Market Capitalization | $328.8 billion |
TTM: trailing 12 months
Dividend payout ratio: 1.51% of net profits
Recently Merck-and-Company has paid out, on average, around 1.51% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.37% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Merck-and-Company shareholders could enjoy a 2.37% return on their shares, in the form of dividend payments. In Merck-and-Company's case, that would currently equate to about $2.96 per share.
While Merck-and-Company's payout ratio might seem low, this can signify that Merck-and-Company is investing more in its future growth.
Merck-and-Company's most recent dividend payout was on 7 July 2024. The latest dividend was paid out to all shareholders who bought their shares by 16 June 2024 (the "ex-dividend date").
Merck-and-Company's shares were split on a 1048:1000 basis on 2 June 2021. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1048 shares. This wouldn't directly have changed the overall worth of your Merck-and-Company shares – just the quantity. However, indirectly, the new 4.6% lower share price could have impacted the market appetite for Merck-and-Company shares which in turn could have impacted Merck-and-Company's share price.
Over the last 12 months, Merck-and-Company's shares have ranged in value from as little as $97.2252 up to $134.63. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Merck-and-Company's is 0.403. This would suggest that Merck-and-Company's shares are less volatile than average (for this exchange).
Merck & Co. , Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners.
Steps to owning and managing ZTEK, with 24-hour and historical pricing before you buy.
Steps to owning and managing MYNZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing ATAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing OWLT, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing HUM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ILMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.